Literature DB >> 18514488

Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology.

Rajiv Tandon1, Matcheri S Keshavan, Henry A Nasrallah.   

Abstract

Although we have studied schizophrenia as a major disease entity over the past century, its causes and pathogenesis remain obscure. In this article, we critically review genetic and other epidemiological findings and discuss the insights they provide into the causes of schizophrenia. The annual incidence of schizophrenia averages 15 per 100,000, the point prevalence averages approximately 4.5 per population of 1000, and the risk of developing the illness over one's lifetime averages 0.7%. Schizophrenia runs in families and there are significant variations in the incidence of schizophrenia, with urbanicity, male gender, and a history of migration being associated with a higher risk for developing the illness. Genetic factors and gene-environment interactions together contribute over 80% of the liability for developing schizophrenia and a number of chromosomal regions and genes have been "linked" to the risk for developing the disease. Despite intensive research and spectacular advances in molecular biology, however, no single gene variation has been consistently associated with a greater likelihood of developing the illness and the precise nature of the genetic contribution remains obscure at this time. Environmental factors linked to a higher likelihood of developing schizophrenia include cannabis use, prenatal infection or malnutrition, perinatal complications, and a history of winter birth; the exact relevance or nature of these contributions is, however, unclear. How various genetic and environmental factors interact to cause schizophrenia and via which precise neurobiological mechanisms they mediate this effect is not understood. Etiological heterogeneity, complex patterns of gene-gene and gene-environment interaction, and inadequately elucidated schizophrenia pathophysiology are among the explanations invoked to explain our inadequate understanding of the etio-pathogenesis of schizophrenia. The ability to question some of our basic assumptions about the etiology and nature of schizophrenia and greater rigor in its study appear critical to improving our understanding about its causation.

Entities:  

Mesh:

Year:  2008        PMID: 18514488     DOI: 10.1016/j.schres.2008.04.011

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  172 in total

Review 1.  Zotepine versus other atypical antipsychotics for schizophrenia.

Authors:  Selvizhi Subramanian; Christine Rummel-Kluge; Heike Hunger; Franziska Schmid; Sandra Schwarz; Werner Kissling; Stefan Leucht; Katja Komossa
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  Positron emission tomography experience with 2-[¹⁸F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[¹⁸F]FA) in the living human brain of smokers with paranoid schizophrenia.

Authors:  James Robert Brašić; Nicola Cascella; Anil Kumar; Yun Zhou; John Hilton; Vanessa Raymont; Andrew Crabb; Maria Rita Guevara; Andrew G Horti; Dean Foster Wong
Journal:  Synapse       Date:  2011-12-29       Impact factor: 2.562

3.  Narcolepsy presenting as schizophrenia: a literature review and two case reports.

Authors:  Farid Ramzi Talih
Journal:  Innov Clin Neurosci       Date:  2011-04

Review 4.  Genetic contributions to behavioural diversity at the gene-environment interface.

Authors:  Andres Bendesky; Cornelia I Bargmann
Journal:  Nat Rev Genet       Date:  2011-11-08       Impact factor: 53.242

5.  The core Gestalt of schizophrenia.

Authors:  Josef Parnas
Journal:  World Psychiatry       Date:  2012-06       Impact factor: 49.548

Review 6.  Uncovering the roles of rare variants in common disease through whole-genome sequencing.

Authors:  Elizabeth T Cirulli; David B Goldstein
Journal:  Nat Rev Genet       Date:  2010-06       Impact factor: 53.242

7.  Nodal centrality of functional network in the differentiation of schizophrenia.

Authors:  Hu Cheng; Sharlene Newman; Joaquín Goñi; Jerillyn S Kent; Josselyn Howell; Amanda Bolbecker; Aina Puce; Brian F O'Donnell; William P Hetrick
Journal:  Schizophr Res       Date:  2015-08-20       Impact factor: 4.939

Review 8.  DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences—part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders.

Authors:  Hans-Jürgen Möller; Borwin Bandelow; Michael Bauer; Harald Hampel; Sabine C Herpertz; Michael Soyka; Utako B Barnikol; Simone Lista; Emanuel Severus; Wolfgang Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-08-26       Impact factor: 5.270

Review 9.  The emerging molecular architecture of schizophrenia, polygenic risk scores and the clinical implications for GxE research.

Authors:  Conrad Iyegbe; Desmond Campbell; Amy Butler; Olesya Ajnakina; Pak Sham
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-01-17       Impact factor: 4.328

10.  Genetic modifiers of abnormal organelle biogenesis in a Drosophila model of BLOC-1 deficiency.

Authors:  Verónica T Cheli; Richard W Daniels; Ruth Godoy; Diego J Hoyle; Vasundhara Kandachar; Marta Starcevic; Julian A Martinez-Agosto; Stephen Poole; Aaron DiAntonio; Vett K Lloyd; Henry C Chang; David E Krantz; Esteban C Dell'Angelica
Journal:  Hum Mol Genet       Date:  2009-12-16       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.